Phenotype, ovarian function, and growth in patients with 45,X/47,XXX Turner mosaicism: Implications for prenatal counseling and estrogen therapy at puberty

被引:26
作者
Blair, J
Tolmie, J
Hollman, AS
Donaldson, MDC [1 ]
机构
[1] Royal Hosp Sick Children, Dept Child Hlth, Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland
[2] Royal Hosp Sick Children, Dept Radiol, Glasgow G3 8SJ, Lanark, Scotland
关键词
D O I
10.1067/mpd.2001.118571
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Our objective was to determine whether girls with the rare Turner 45, X/47, XXX mosaic karyotype are less severely affected than girls with 2 commoner karyotypes. Study design: We evaluated growth status, phenotype, and ovarian Function in 7 girls with 45, X/47, XXX mosaicism, age-matching each with 2 girls with 45, X and 1 with 45, X/46, Xi(X) (q10) karyotypes. Results: For the index, 45, X, and 45, X/46, Xi(X) (q10) groups, respectively, the median/mean height SD score at the start of growth hormone therapy/comparable age was -2.0 (-1.2), -2.3 (-2.4), and -2.6 (-2.6), cardiac anomalies were identified in 0 of 7, 4 of 14, and 1 of 7, renal abnormalities in 0 of 7, 4 of 14, and 3 of 7, middle ear problems in 2 of 7, 11 of 14, and 4 of 7, and special educational needs in 0 of 7, 3 of 14, and 1 of 7. Complete spontaneous puberty with menarche was seen in all but 1 girl older than 12 years in the index group compared with only 1 girl in the comparison groups. Ovarian tissue was identified in 6 of 7, 0 of 14, and 1 of 7 girls, and the mean follicle-stimulating hormone was 6, 25, and 21 U/L, respectively. Conclusion: Girls with 45, X/47, XXX karyotype are mildly affected, with good preservation of ovarian function. This result has important implications Cor prenatal counseling and the need for estrogen therapy at puberty.
引用
收藏
页码:724 / 728
页数:5
相关论文
共 27 条
[1]  
BENDER B, 1984, PEDIATRICS, V73, P175
[2]  
BENDER BG, 1995, PEDIATRICS, V96, P302
[3]   FINAL HEIGHT OF GIRLS WITH TURNERS-SYNDROME - CORRELATION WITH KARYOTYPE AND PARENTAL HEIGHT [J].
COHEN, A ;
KAULI, R ;
PERTZELAN, A ;
LAVAGETTO, A ;
ROITMAN, Y ;
ROMANO, C ;
LARON, Z .
ACTA PAEDIATRICA, 1995, 84 (05) :550-554
[4]  
DEKERDANET M, 1994, CLIN ENDOCRINOL, V41, P673
[5]   Prevalence of renal malformation in Turner syndrome [J].
Flynn, MT ;
Ekstrom, L ;
DeArce, M ;
Costigan, C ;
Hoey, HM .
PEDIATRIC NEPHROLOGY, 1996, 10 (04) :498-500
[6]   CROSS-SECTIONAL STATURE AND WEIGHT REFERENCE CURVES FOR THE UK 1990 [J].
FREEMAN, JV ;
COLE, TJ ;
CHINN, S ;
JONES, PRM ;
WHITE, EM ;
PREECE, MA .
ARCHIVES OF DISEASE IN CHILDHOOD, 1995, 73 (01) :17-24
[7]   PREVALENCE OF CARDIOVASCULAR MALFORMATIONS AND ASSOCIATION WITH KARYOTYPES IN TURNERS-SYNDROME [J].
GOTZSCHE, CO ;
KRAGOLSEN, B ;
NIELSEN, J ;
SORENSEN, KE ;
KRISTENSEN, BO .
ARCHIVES OF DISEASE IN CHILDHOOD, 1994, 71 (05) :433-436
[8]   PELVIC ULTRASOUND MEASUREMENTS IN NORMAL GIRLS [J].
GRIFFIN, IJ ;
COLE, TJ ;
DUNCAN, KA ;
HOLLMAN, AS ;
DONALDSON, MDC .
ACTA PAEDIATRICA, 1995, 84 (05) :536-543
[9]   THYROID AUTOANTIBODIES, TURNERS-SYNDROME AND GROWTH-HORMONE THERAPY [J].
IVARSSON, SA ;
ERICSSON, UB ;
NILSSON, KO ;
GUSTAFSSON, J ;
HAGENAS, L ;
HAGER, A ;
MOELL, C ;
TUVEMO, T ;
WESTPHAL, O ;
ALBERTSSONWIKLAND, K ;
AMAN, J .
ACTA PAEDIATRICA, 1995, 84 (01) :63-65
[10]  
KLECZKOWSKA A, 1990, Genetic Counseling, V1, P227